LY3471851

Drug identity checked against registry records

Also recorded as NKTR-358; REZPEG; Rezpegaldesleukin

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)NCT04677179NKTRPhase 2Terminated2022-08-09Actual
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)NCT04433585NKTRPhase 2Completed2023-01-10Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.